Shanghai Yizhong: Net profit in 2025 was 64.132 million yuan, a year-on-year increase of 819.42%.

Shanghai Yizhong released its performance report, achieving an operating income of 317 million yuan in 2025, an increase of 82.72% year-on-year. Net profit was 641.32 million yuan, an increase of 819.42% year-on-year. The company's core product, paclitaxel polymer micelles for injection, was officially included in the national medical insurance catalog in 2025, significantly increasing market access and the number of users, driving the company's full-year revenue and profit growth.